Lupin Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Mid Cap

Lupin has allotted 59,809 equity shares under ESOP on 18 April 2024. The issued and paid-up capital of the Company has been increased tot 91,15,00,208 consisting of 45,57,50, 104 equity shares of Rs 2/- each.

Powered by Capital Market - Live News

Lupin announced that the United States Food and Drug Administration (U.S. FDA) has completed a GMP Inspection of its API manufacturing facility located at Dabhasa, India. The inspection was conducted from 08 April to 12 April 2024 and concluded with no observations.

Powered by Capital Market - Live News

The USFDA conducted a good manufacturing practices (GMP) inspection from 8 April 2024 to 12 April 2024.

Nilesh Gupta, managing director of Lupin said, “This accomplishment underscores our unwavering dedication to maintaining the highest standards of quality and compliance in all aspects of our operations.”

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.

The pharmaceutical company reported consolidated net profit of Rs 613.12 crore in Q3 FY24, steeply higher than Rs 153.47 crore posted in Q3 FY23. Revenue from operations increased 19.67% YoY to Rs 5,079.88 crore in the quarter ended 31 December 2023.

Powered by Capital Market - Live News

Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients.

According to IQVIA MAT February 2024, Doxycycline Capsules had estimated annual sales of $128 million in the U.S.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle East regions.

The pharmaceutical company reported consolidated net profit of Rs 613.12 crore in Q3 FY24, steeply higher than Rs 153.47 crore posted in Q3 FY23. Revenue from operations increased 19.67% YoY to Rs 5,079.88 crore in the quarter ended 31 December 2023.

The scrip fell 0.47% to ends at Rs 1,605.05 on Tuesday, 9 April 2024.

Powered by Capital Market - Live News